| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/26/2001 | WO2001052851A1 Methods for the treatment of substance abuse |
| 07/26/2001 | WO2001052844A1 Brain, spinal and nerve injury treatment |
| 07/26/2001 | WO2001052842A1 Compositions for the prevention of diaper dermatitis |
| 07/26/2001 | WO2001052839A1 Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes |
| 07/26/2001 | WO2001052832A1 Ocular growth and nicotinic antagonists |
| 07/26/2001 | WO2001052829A2 Statin-type bone growth stimulators |
| 07/26/2001 | WO2001052827A1 Control of microbial populations in the gastrointestinal tract of animals |
| 07/26/2001 | WO2001052825A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | WO2001017543A3 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 07/26/2001 | WO2001014886A3 Inhibitors of binding between proteins and macromolecular ligands |
| 07/26/2001 | WO2000078933A3 Novel calpains and their use |
| 07/26/2001 | WO2000078803A3 Use of eif4e binding agents in therapy |
| 07/26/2001 | WO2000071741A9 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 07/26/2001 | WO2000070341A3 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/26/2001 | WO2000069445A8 Combination therapy for treating hypercholesterolemia |
| 07/26/2001 | WO2000066156A8 Death domain containing receptor 5 |
| 07/26/2001 | WO2000059547A3 Method of detecting endometriosis |
| 07/26/2001 | US20010009922 An agent to induce expressioon of a product, e.g. thymidinekinase, in viral-infected cell to increase the sensitivity to the viricide whose activity is directed to the expressed product; antiproliferative agent |
| 07/26/2001 | US20010009920 Combination therapy for osteoporosis |
| 07/26/2001 | US20010009907 Compositions and methods for preventing restenosis following revascularization procedures |
| 07/26/2001 | US20010009906 Treatment of HIV-infected human in alternation or combination with second anti-HIV drug that induces mutation pattern at other than 70th codon of reverse transcriptase region location; drug resistance, pharmokinetics |
| 07/26/2001 | US20010009905 Adipocyte Complement-Related Protein encoded polypeptides, used in therapy and diagnosis, cell proliferation, cell death, energy homestasis; treatment of cancers, obesity, diabetes, heart disease, immunity |
| 07/26/2001 | DE19961141A1 Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen The pharmaceutical composition of spider venoms as well as their preparation and use for the treatment of tumor diseases |
| 07/26/2001 | DE10001172A1 Templatieren von Feststoffpartikeln mit Polymermultischichten Templating of solid particles with polymer multilayers |
| 07/26/2001 | DE10000651A1 Identifying inhibitors and activators of eukaryotic potassium channels, for use as pharmaceuticals, comprises using yeast cells that express heterologous, but no endogenous, potassium channels |
| 07/26/2001 | CA2743326A1 High purity lipopeptides, lipopeptide micelles and processes for preparing same |
| 07/26/2001 | CA2673615A1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | CA2400803A1 Ocular growth and nicotinic antagonists |
| 07/26/2001 | CA2398710A1 Egg specific surface proteins |
| 07/26/2001 | CA2398695A1 Chondromodulin-i related peptide |
| 07/26/2001 | CA2398256A1 Methods for detecting cancer of the central nervous system |
| 07/26/2001 | CA2397946A1 Lipid metabolism enzymes |
| 07/26/2001 | CA2397919A1 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
| 07/26/2001 | CA2397863A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| 07/26/2001 | CA2397838A1 Sperm specific proteins |
| 07/26/2001 | CA2397833A1 Novel haptotactic peptides |
| 07/26/2001 | CA2397830A1 Compositions for the prevention of diaper dermatitis |
| 07/26/2001 | CA2397802A1 Calcilytic compounds |
| 07/26/2001 | CA2397783A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | CA2397774A1 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | CA2397726A1 Methods for the treatment of substance abuse |
| 07/26/2001 | CA2397665A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | CA2397659A1 Statin-type bone growth stimulators |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397617A1 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 07/26/2001 | CA2397598A1 Combinations for treating neoplasms |
| 07/26/2001 | CA2397571A1 Apoptin-associating protein |
| 07/26/2001 | CA2397065A1 Compositions for delivery of a cortisol antagonist |
| 07/26/2001 | CA2396935A1 Phosphatases |
| 07/26/2001 | CA2396319A1 Ophthalmic compositions for treating ocular hypertension |
| 07/26/2001 | CA2394612A1 Antimicrobial compositions |
| 07/26/2001 | CA2389924A1 Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes |
| 07/26/2001 | CA2365610A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | CA2332214A1 Compositions and methods for treating osteoporosis and lowering cholesterol |
| 07/26/2001 | CA2332208A1 Pharmacophore models for, methods of screening for, and identification of the cytochrome p-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 07/25/2001 | EP1118858A2 Assay method |
| 07/25/2001 | EP1118680A1 Method for the diagnosis of polymorphisms in the human PDH E1alpha gene |
| 07/25/2001 | EP1118678A1 Method for diagnosing polymorphisms in the human PDH E1 beta gene |
| 07/25/2001 | EP1118663A1 Nucleic acids encoding chemotaxis inhibitory polypeptides |
| 07/25/2001 | EP1118332A1 A composition for treating degenerative joint diseases |
| 07/25/2001 | EP1118322A1 Drugs for improving vesical excretory strength |
| 07/25/2001 | EP1117840A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 07/25/2001 | EP1117836A2 Expressionanalysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 07/25/2001 | EP1117824A1 Use of s-ydcb and b-ydcb, essential bacterial genes |
| 07/25/2001 | EP1117791A2 Cancer associated antigens and uses therefor |
| 07/25/2001 | EP1117787A2 Slgp protein and nucleic acid molecule and uses therefor |
| 07/25/2001 | EP1117785A1 Human kinesin-like motor protein |
| 07/25/2001 | EP1117782A2 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 07/25/2001 | EP1117778A2 Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| 07/25/2001 | EP1117762A1 Methods of controlling proliferation and differentiation of stem and progenitor cells |
| 07/25/2001 | EP1117736A1 Modified starch film compositions |
| 07/25/2001 | EP1117680A2 Ncam binding compounds |
| 07/25/2001 | EP1117444A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 07/25/2001 | EP1117442A1 Dry powder active agent pulmonary delivery |
| 07/25/2001 | EP1117441A2 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 07/25/2001 | EP1117439A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 07/25/2001 | EP1117437A1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke |
| 07/25/2001 | EP1117436A1 Neisseria spp polypeptide, nucleic acid sequence and uses thereof |
| 07/25/2001 | EP1117432A1 Carbohydrate vaccines for viral diseases |
| 07/25/2001 | EP1117427A2 USE OF $i(PEX) IN THE TREATMENT OF METABOLIC BONE DISEASES |
| 07/25/2001 | EP1117426A2 Akt compositions for enhancing survival of cells |
| 07/25/2001 | EP1117425A2 Methods for the treatment of non-thyroid disorders |
| 07/25/2001 | EP1117405A2 Composition and method for treating allergic diseases |
| 07/25/2001 | EP1117403A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 07/25/2001 | EP1117402A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/25/2001 | EP1117401A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/25/2001 | EP1117398A2 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/25/2001 | EP1117396A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 07/25/2001 | EP1117392A1 Method for preventing or delaying catheter-based revascularization |
| 07/25/2001 | EP1117390A1 Mucosal originated drug delivery systems and animal applications |
| 07/25/2001 | EP1117378A2 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 07/25/2001 | CN1305589A Improved immunodiagnostic assays using reducing agents |
| 07/25/2001 | CN1305527A Vasculogenesis correlation molecule |
| 07/25/2001 | CN1305387A Enhancement of antibody-cytokine fusion protein medicated immune responses by co-administration with prostaglandin inhibitor |
| 07/25/2001 | CN1305386A Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 07/25/2001 | CN1305385A Method and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 07/25/2001 | CN1305380A Use of composition comprising Formoterol and Budesonide for prevention or treatment of acute condition of asthma |
| 07/25/2001 | CN1305377A Methods for increasing levels of acetylcholine |
| 07/25/2001 | CN1305376A Pharmaceutical composition for treatment of diabetes |
| 07/25/2001 | CN1305343A Methods for increasing levels of acetylchotine |